REITs report mixed FY2025 guidance and earnings, with some seeing margin improvements but facing analyst forecasts of future earnings and margin declines.
BridgeBio reports positive Phase 3 results for two late-stage candidates, encaleret and BBP-418, driving a sharp rally in the company's shares.
Globe Life reports strong Q3 results driven by growth in life and health insurance underwriting, maintaining its position as a reliable investment in the financial sector.
REITs report mixed FY2025 guidance and earnings, with some seeing margin improvements but facing analyst forecasts of future earnings and margin declines.
BridgeBio reports positive Phase 3 results for two late-stage candidates, encaleret and BBP-418, driving a sharp rally in the company's shares.
Globe Life reports strong Q3 results driven by growth in life and health insurance underwriting, maintaining its position as a reliable investment in the financial sector.